Quick Answer
Decoy Therapeutics Inc. reported R&D Expense of $368.2 thousand for fiscal year 2025.
Decoy Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $368.2K | -52.2% |
| 2024 | $770.0K | -89.3% |
| 2023 | $7.17M | -54.7% |
| 2022 | $15.84M | +85.3% |
| 2021 | $8.55M | +23.6% |
| 2020 | $6.91M | +72.0% |
| 2019 | $4.02M | +212.1% |
| 2018 | $1.29M | -92.4% |
| 2017 | $16.99M | -16.6% |
| 2016 | $20.38M | +59.8% |
| 2015 | $12.75M | +42365.4% |
| 2014 | $30.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $61.8K | -54.9% | -46.9% |
| June 30, 2025 | $116.4K | -45.7% | +54.1% |
| March 31, 2025 | $75.5K | -68.9% | -45.0% |
| September 30, 2024 | $137.2K | -86.8% | -36.0% |
| June 30, 2024 | $214.4K | -90.9% | -11.8% |
| March 31, 2024 | $243.0K | -93.5% | -76.6% |
| September 30, 2023 | $1.04M | -72.7% | -55.9% |
| June 30, 2023 | $2.35M | -19.5% | -36.9% |
- Decoy Therapeutics Inc. showed a decrease of -52.2% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Decoy Therapeutics Inc.’s r&d expense has grown by 1126.3% (from $30.0 thousand to $368.2 thousand).
- The most recent figure is from Decoy Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: